Clinical Trial Update: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] [Phase 3]

View source ↗

Summary

Phase 3 PALOMA-4 evaluated palbociclib plus letrozole versus placebo plus letrozole as first-line therapy in Asian postmenopausal women with ER+/HER2- advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2021-11-18